RATE OF THROMBOSIS IN CONTEMPORARY PATIENTS WITH POLYCYTHEMIA VERA UNDER HYDROXYUREA REMAINS EXCEEDINGLY HIGH. RESULTS OF SYSTEMATIC REVIEW AND METANALYSIS.
Author(s): ,
Alberto Ferrari
Affiliations:
FROM research foundation,Bergamo,Italy
,
Alessandra Carobbio
Affiliations:
FROM research foundation,Bergamo,Italy
,
Arianna Masciulli
Affiliations:
FROM research foundation,Bergamo,Italy
,
Arianna Ghirardi
Affiliations:
FROM research foundation,Bergamo,Italy
,
Guido Finazzi
Affiliations:
Hematology Division, Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Valerio De Stefano
Affiliations:
Institute of Hematology, Catholic University, Fondazione Policlinico Universitario A. Gemelli IRCCS,Roma,Italy
,
Alessandro Maria Vannucchi
Affiliations:
CRIMM-Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi,Firenze,Italy;Dept. Experimental and Clinical medicine,University of Florence,Firenze,Italy
Tiziano Barbui
Affiliations:
FROM research foundation,Bergamo,Italy
EHA Library. Ferrari A. Jun 14, 2019; 266470; PF671
Dr. Alberto Ferrari
Dr. Alberto Ferrari
Contributions
Abstract

Abstract: PF671

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background

Hydroxyurea (HU) is the recommended first line therapy in high risk polycythemia vera (PV) based on the results of PVSG protocol 08. In this prospective observational study, HU was more effective in reducing the rate of thrombotic events in 51 patients in comparison with historical controls treated with phlebotomy (PHL) alone. Since then, very few studies confirmed these results. Recently, a propensity score analysis of patients enrolled in the ECLAP trial documented superiority of HU in reducing thrombosis compared to PHL only. HU was compared to Interferon (IFN) in three recent randomized controlled trials in PV; unfortunately, primary end-point of these trials was not the reduction of vascular complications but only hematological response, which is not deemed a valid surrogate of vascular events.

Aims
We performed a meta-analysis to determine the absolute risk of thrombosis, bleeding, acute myelogenous leukemia (AML) and myelofibrosis (MF) in contemporary patients (2008-2018) under HU treatment. 

Methods

We searched for relevant articles or abstracts in the following databases: Medline, EMBASE, clinicaltrials.gov, WHO International Clinical Trials Registry, LILACS.

Sixteen out of 429 published studies reporting number of events using WHO diagnostic classification for PV, met the criteria of our study protocol (registered in PROSPERO; number CRD42018117814). Through a random effect logistic model, incidences, study heterogeneity and effects of confounders were estimated for each outcome at different follow-ups.

Results
Events were collected in 3,236 PV patients, during a mean follow-up ranging from 0.3 to 12.4 years.

Thrombosis: Overall major thrombosis incidence (n=469) was about 3% per year, obtained by pooling event rates from each study. In meta-regression analysis accounting for study-specific confounders such as median age, antithrombotic therapy, cardio-vascular risk factors and history of thrombosis, a slightly lower estimate of 2.8%.was found. This rate did not change over follow-up time, as shown by a comparison between a logistic and a negative binomial model, and depended on age. Annual estimates of major thrombosis in patients with a median age of 60, 70 and 80 years were 1.6%, 3.6% and 6.8% respectively. This incidence is approximately 10-fold higher than the one estimated in the general population.

Bleeding: Based on 88 events over 1,485 patients, bleeding pooled incidence was 1% per year, independently of follow-up duration and antithrombotic therapy, as shown by meta-regression.

Hematological transformations and mortality: Annual rate of AML (n=63) was fairly constant over time and the cumulative 10-year incidence was about 4% (0.4% patients/year). In contrast, rate of evolution into MF (n=157), as predicted by meta-regression, increased steeply after 5 years of follow-up. In the 0-5/5-10 years of follow-up the average annual rate of MF evolution was 1.0% and 5.1% respectively. Mortality (n=522) followed a similar pattern as MF. Estimates were 2.4%, 12.6% and 56.2% at 1, 5 and 10 years respectively.

 

Conclusion

The results of this meta-analysis can be a valid reference for patient communication and counseling, and also constitute a help for sample size calculations in future comparative clinical trials adopting hard efficacy endpoints (thrombosis) in selected populations.  

Session topic: 16. Myeloproliferative neoplasms - Clinical

Keyword(s): Hydroxyurea, Myelofibrosis, Polycythemia vera, Thrombosis

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies